Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently expe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Haematologica
Autori principali: Boudny, Miroslav, Zemanova, Jana, Khirsariya, Prashant, Borsky, Marek, Verner, Jan, Cerna, Jana, Oltova, Alexandra, Seda, Vaclav, Mraz, Marek, Jaros, Josef, Jaskova, Zuzana, Spunarova, Michaela, Brychtova, Yvona, Soucek, Karel, Drapela, Stanislav, Kasparkova, Marie, Mayer, Jiri, Paruch, Kamil, Trbusek, Martin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6959166/
https://ncbi.nlm.nih.gov/pubmed/30975914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.203430
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi